|
Gene: WDR7 |
Gene summary for WDR7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | WDR7 | Gene ID | 23335 |
Gene name | WD repeat domain 7 | |
Gene Alias | TRAG | |
Cytomap | 18q21.31 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9Y4E6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23335 | WDR7 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.77e-15 | 6.80e-01 | -0.2116 |
23335 | WDR7 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.14e-02 | 4.43e-01 | -0.2107 |
23335 | WDR7 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 8.73e-13 | 6.53e-01 | -0.2119 |
23335 | WDR7 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 3.62e-04 | 2.64e-01 | -0.0166 |
23335 | WDR7 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.15e-02 | 1.89e-01 | -0.0132 |
23335 | WDR7 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.56e-03 | 2.09e-01 | -0.013 |
23335 | WDR7 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.17e-02 | 2.01e-01 | -0.0121 |
23335 | WDR7 | HTA12-15-2 | Human | Pancreas | PDAC | 3.34e-04 | 4.26e-01 | 0.2315 |
23335 | WDR7 | HTA12-23-1 | Human | Pancreas | PDAC | 1.68e-12 | 9.53e-01 | 0.3405 |
23335 | WDR7 | HTA12-26-1 | Human | Pancreas | PDAC | 1.16e-23 | 1.02e+00 | 0.3728 |
23335 | WDR7 | HTA12-29-1 | Human | Pancreas | PDAC | 2.73e-37 | 8.39e-01 | 0.3722 |
23335 | WDR7 | HTA12-30-1 | Human | Pancreas | PDAC | 4.63e-02 | 9.00e-01 | 0.3671 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Lung | AAH: Atypical adenomatous hyperplasia | |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
GO:002241110 | Cervix | CC | cellular component disassembly | 83/2311 | 443/18723 | 6.04e-05 | 8.68e-04 | 83 |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
GO:00510528 | Cervix | CC | regulation of DNA metabolic process | 65/2311 | 359/18723 | 9.25e-04 | 7.84e-03 | 65 |
GO:0030198 | Cervix | CC | extracellular matrix organization | 52/2311 | 301/18723 | 7.43e-03 | 3.98e-02 | 52 |
GO:0043062 | Cervix | CC | extracellular structure organization | 52/2311 | 302/18723 | 7.92e-03 | 4.17e-02 | 52 |
GO:0022617 | Cervix | CC | extracellular matrix disassembly | 15/2311 | 63/18723 | 8.52e-03 | 4.40e-02 | 15 |
GO:0031214 | Cervix | CC | biomineral tissue development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
GO:0045229 | Cervix | CC | external encapsulating structure organization | 52/2311 | 304/18723 | 9.00e-03 | 4.57e-02 | 52 |
GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
GO:1903320 | Colorectum | AD | regulation of protein modification by small protein conjugation or removal | 86/3918 | 242/18723 | 9.43e-08 | 4.65e-06 | 86 |
GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
GO:0031396 | Colorectum | AD | regulation of protein ubiquitination | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
GO:0031056 | Colorectum | AD | regulation of histone modification | 45/3918 | 152/18723 | 7.05e-03 | 4.31e-02 | 45 |
GO:19033201 | Colorectum | SER | regulation of protein modification by small protein conjugation or removal | 70/2897 | 242/18723 | 6.84e-08 | 4.42e-06 | 70 |
GO:00313961 | Colorectum | SER | regulation of protein ubiquitination | 62/2897 | 210/18723 | 1.69e-07 | 9.71e-06 | 62 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR7 | SNV | Missense_Mutation | novel | c.3521A>G | p.His1174Arg | p.H1174R | Q9Y4E6 | protein_coding | tolerated(0.19) | possibly_damaging(0.888) | TCGA-55-8614-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
WDR7 | SNV | Missense_Mutation | c.4373N>T | p.Gly1458Val | p.G1458V | Q9Y4E6 | protein_coding | tolerated(0.43) | probably_damaging(0.998) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD | |
WDR7 | SNV | Missense_Mutation | c.1076N>T | p.Ser359Leu | p.S359L | Q9Y4E6 | protein_coding | deleterious(0.02) | benign(0.006) | TCGA-64-1679-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
WDR7 | SNV | Missense_Mutation | c.4241N>G | p.Asn1414Ser | p.N1414S | Q9Y4E6 | protein_coding | tolerated(0.42) | benign(0.137) | TCGA-78-7633-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
WDR7 | SNV | Missense_Mutation | c.4363N>C | p.Ala1455Pro | p.A1455P | Q9Y4E6 | protein_coding | tolerated(0.07) | possibly_damaging(0.9) | TCGA-86-8672-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
WDR7 | SNV | Missense_Mutation | c.4217N>T | p.Gly1406Val | p.G1406V | Q9Y4E6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
WDR7 | SNV | Missense_Mutation | novel | c.2884N>T | p.Asp962Tyr | p.D962Y | Q9Y4E6 | protein_coding | deleterious(0.02) | benign(0.261) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
WDR7 | SNV | Missense_Mutation | c.1549C>G | p.Gln517Glu | p.Q517E | Q9Y4E6 | protein_coding | deleterious(0.03) | probably_damaging(0.93) | TCGA-97-A4M5-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
WDR7 | SNV | Missense_Mutation | c.1297G>T | p.Val433Leu | p.V433L | Q9Y4E6 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-97-A4M7-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
WDR7 | SNV | Missense_Mutation | c.1977N>T | p.Glu659Asp | p.E659D | Q9Y4E6 | protein_coding | tolerated(0.72) | benign(0) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |